In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib, which help slow cancer cell division. Immunotherapy: For some patients with triple-negative breast cancer (which lacks hormone receptors ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

Revenue: Revenue was $0 for the third quarter of 2024, as compared to $25.2 million for the third quarter of 2023. The decrease was primarily due to the recognition of previously received milestone ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) have been assigned a consensus rating of “Buy” from the ...

A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...

On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE ...

Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Among the many impactful sessions, a symposium titled ‘Incorporating Novel Treatment Insights for Estrogen Receptor-Positive (ER+) Early Breast Cancer Patients’ garnered particular attention.

Penelope Oliver, a volunteer with Students Demand Action in California, talks to Hal about state laws involving firearms.